Adjusting Chemotherapy Dose by Muscle Mass May Reduce Nerve Damage in Colon Cancer Patients

For patients with stage III colon cancer, chemotherapy with oxaliplatin after surgery is a standard treatment. While effective, oxaliplatin often causes nerve damage (neuropathy), leading to numbness, tingling, or pain in the hands and feet. These side effects can be long-lasting and affect daily life.

A new clinical trial called LEANOX tested whether adjusting the oxaliplatin dose based on a patient’s lean body mass (muscle mass), rather than just body size, could lower the risk of nerve damage.

In the study, patients with low muscle mass were split into two groups: one received the usual dose based on body size, while the other received a lower dose adjusted to their muscle mass.

The results showed that patients who received the muscle mass-based dose had far fewer cases of serious nerve problems. About two-thirds of these patients avoided significant neuropathy, compared with less than half in the standard dosing group. They also needed fewer dose cuts, tolerated more chemotherapy, and reported a better quality of life.

Importantly, adjusting the dose did not affect survival. Patients in both groups lived just as long and had the same chance of staying cancer-free after treatment.

This study suggests that tailoring chemotherapy doses to muscle mass could protect patients from one of the most disabling side effects of oxaliplatin, without reducing its effectiveness.